Man Group plc Invests $11.08 Million in Medpace Holdings, Inc. $MEDP

Man Group plc bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,926 shares of the company’s stock, valued at approximately $11,082,000. Man Group plc owned approximately 0.07% of Medpace at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. BOKF NA grew its stake in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. grew its position in shares of Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after purchasing an additional 24 shares during the last quarter. Schulhoff & Co. Inc. grew its holdings in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC raised its stake in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after purchasing an additional 26 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $600.65 on Friday. The stock has a market capitalization of $16.76 billion, a PE ratio of 35.21, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The stock has a 50 day moving average price of $565.33 and a two-hundred day moving average price of $494.55.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on MEDP shares. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and lifted their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 133,821 shares of company stock worth $81,748,135. Corporate insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.